Literature DB >> 8830071

Withdrawal syndromes after paroxetine and sertraline discontinuation.

G A Fava, S Grandi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8830071     DOI: 10.1097/00004714-199510000-00012

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

Review 1.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

2.  Hypotension following cardiac surgery associated with paroxetine and mirtazapine withdrawal.

Authors:  Kimberly J Novak; William I Douglas; Robert J Kuhn
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

3.  Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.

Authors:  Filippo Bogetto; Silvio Bellino; Raffaele Bonatto Revello; Luca Patria
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Authors:  K Black; C Shea; S Dursun; S Kutcher
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

5.  A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.

Authors:  Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John Martin Corkery; Giovanni Martinotti; Fabrizio Schifano
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-01

6.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.